Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Levetiracetam: a review of its use in epilepsy.
- K. Lyseng-Williamson
- 5 March 2011
Oral levetiracetam provided seizure control relative to placebo as adjunctive therapy in patients with idiopathic generalized epilepsy with myoclonic seizures or GTC seizures and showed improvements in measures of health-related quality of life relative to those receiving placebo. Expand
Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
Tamsulosin, an alpha1-adrenoceptor antagonist, has a well established place in the treatment of LUTS and has a tolerability profile similar to that of placebo (apart from a higher incidence of abnormal ejaculation, dizziness and rhinitis). Expand
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Oral tenofovir DF 300 mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Expand
Meropenem: a review of its use in the treatment of serious bacterial infections.
Its low propensity for inducing seizures means that it is suitable for treating bacterial meningitis and is the only carbapenem approved in this indication. Expand
Clopidogrel: a review of its use in the prevention of thrombosis.
Results of several large randomised trials have established clopidogrel as an effective and well tolerated antiplatelet agent for the secondary prevention of ischaemic events in patients with various cardiovascular conditions, including those with ischaemia stroke or acute coronary syndromes. Expand
Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes.
Famciclovir is a well tolerated first-line option for the treatment of herpes zoster and the treatment and suppression of genital herpes, and is approved for the Treatment of recurrent orolabial herpes. Expand
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
- K. Lyseng-Williamson
In patients with advanced NSCLC, second- or third-line treatment with erlotinib is clinically effective in improving survival and cost advantages were predicted across analyses, regardless of the type of model developed, specific costs that were included, country that the study was conducted in and year of costing. Expand
Docetaxel: a review of its use in metastatic breast cancer.
Although docetaxel is associated with neutropenia and other adverse events, its overall tolerability profile is generally acceptable in the majority of patients and is an effective option in the treatment of patients with metastatic breast cancer after failure of prior chemotherapy. Expand
Topiramate: a review of its use in the treatment of epilepsy.
Topiramate (Topamax) is a structurally novel broad-spectrum antiepileptic drug (AED) with established efficacy as monotherapy or adjunctive therapy in the treatment of adult and paediatric patients… Expand
Etanercept: a review of its use in the management of rheumatoid arthritis.
Etanercept plus methotrexate combination therapy was generally superior to either monotherapy or combination therapy in reducing disease activity and structural joint damage, as well as improving health-related quality of life (HR-QOL). Expand